Nautilus Biotechnology Inc
(NAS:NAUT)
$
2.73
-0.02 (-0.73%)
Market Cap: 342.37 Mil
Enterprise Value: 210.04 Mil
PE Ratio: 0
PB Ratio: 1.47
GF Score: 39/100 Nautilus Biotechnology Inc at Goldman Sachs Healthcare Conference Transcript
Jun 12, 2023 / 11:40PM GMT
Release Date Price:
$3.58
(+8.16%)
Elizabeth V. Koslosky
Goldman Sachs Group, Inc., Research Division - Research Analyst
Okay. It looks like we can go ahead and get started. So hi, everyone. I'm Evie Koslosky. I'm on the Tools and Diagnostics team at GS. I'm here with Sujal Patel from Nautilus. Thank you for joining us.
Sujal M. Patel
Nautilus Biotechnology, Inc. - Co-Founder, CEO, President, Secretary & Director
Thanks, Evie. Thanks for having us.
Questions & Answers
Elizabeth V. Koslosky
Goldman Sachs Group, Inc., Research Division - Research Analyst
And I think just to get started, it would be helpful to set the stage a little bit, give us a brief overview of the business, particularly the role models that's playing within proteomics and the technology in the process of developing.
Sujal M. Patel
Nautilus Biotechnology, Inc. - Co-Founder, CEO, President, Secretary & Director
Great. Well, so Nautilus Biotechnology is a 6.5-year-old development-stage proteomics company. Before I
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot